News

Trial Testing Psilocybin in Parkinson’s Nears End

A clinical trial testing the impact of low doses of psilocybin, a naturally occurring psychedelic compound, on inflammatory activity in people with Parkinson’s disease is on track to be completed by the end of February. Sponsored by Silo Pharma and conducted at the Clinical & Translational Science Institute (CTSI)…

Inflammatory Gut Bacteria, Genes May Be Parkinson’s Biomarkers

Certain pro-inflammatory gut bacteria, genes, and pathways are significantly increased in people with Parkinson’s disease compared with healthy people, while anti-inflammatory ones are significantly reduced, a large study found. Also, machine learning models based on 11 of these bacteria and six of these genes accurately discriminated between people with…

Mediterranean Diets Linked to Reduced Symptom Burden

Better adherence to Mediterranean-style diets is associated with lower patient-reported symptom severity in people with Parkinson’s disease, according to a study of more than 1,000 patients. Between the two evaluated diets — the Mediterranean (MEDI) and the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) — the MIND diet was…